Navigation Links
InspireMD Announce the Completion of Enrollment for the MAGICAL Trial (MGuard(TM) in Acute Myocardial Infarction) at EuroPCR '09. Results Will be Presented May 21st by Dr. Dariusz Dudek at the InspireMD Cocktail Reception Debate Chaired by Prof. Martin Le
Date:5/21/2009

BARCELONA, Spain, May 20 /PRNewswire/ -- InspireMD, Ltd. announced today the completion of enrolment for the MAGICAL trial (MGuard(TM) in Acute Myocardial). The trial was designed to confirm the clinical feasibility, safety and performance of MGuard when used during Primary PCI in STEMI patients.

The MAGICAL trial is a multicenter, prospective, single arm, 60 patients study (Principal investigator: Dr. Dariusz Dudek, Jagiellonian University, Krakow, Poland). Primary end-points are incidence of complete ST segment resolution measured 60 minutes post procedure and incidence of TIMI 3 flow after PCI. Main secondary endpoints are myocardial blush grade and MACE (major adverse cardiac events) at discharge, 30 days and 6 months.

"I am very pleased and excited we reached this milestone" said Dr. Dariusz Dudek, the MAGICAL Study Chief Investigator, from Jagiellonian University in Krakow. "From the data collected so far, primary PCI for STEMI patients using MGuardTM seems highly safe and effective".

To date, TIMI flow 3 is 91%, MBG 3 (Myocardial Blush Grade) is 74%, Complete ST Resolution is 63%. MACE at discharge is 0% and 30 days MACE to date is 0% as well.

"This important milestone is getting us closer to confirm MGuard's important role in the treatment of acute MI patients, by providing a comprehensive solution to the distal embolization threat" said Eli Bar, CTO and VP R&D at InspireMD. "So far, the MAGICAL Trial results are confirming what we had experienced in cath-labs around the world; that the MGuardTM performs well and delivers extra safety for the patients".

A presentation of the updated results of the MAGICAL trial by Dr. Dariusz Dudek will be given at the InspireMD Cocktail Reception, May 21st at 18:30 at the Hilton Diagonal Mar, next to the EuroPCR conference CCIB Conference center. The Cocktail Reception and Debate: "What is the Best Strategy in Acute M
'/>"/>

SOURCE InspireMD
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. MGuard(TM), InspireMDs Novel Coronary Stent System, was Celebrated by World Leading Interventional Cardiologists at the Transcatheter Cardiovascular Therapeutics (TCT) in Washington DC, USA, October 12-17 2008
2. InspireMD Announces Enrollment of First Patients in the MGuard(TM) Acute Myocardial Infarction Clinical Trial Data Will be Used to Confirm Initial Positive Results
3. Cephalon Announces Proposed Public Offering of Common Stock and Convertible Senior Subordinated Notes
4. Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer
5. Martek to Announce Second Quarter 2009 Results
6. Aesthera Announces ANVISA Clearance to Market Photopneumatic Platforms in Brazil
7. The Hamner Institutes Announce Partnership With China Medical City
8. Oncothyreon announces commitments to purchase $11.1 million of company securities in a registered direct financing
9. Beckman Coulter, Inc. Announces Pricing of Common Stock Offering
10. MedClean Technologies, Inc. Announces Private Offer to Exchange Warrants
11. Angiotechs corporate partner, Boston Scientific, announces launch of third-generation TAXUS(R) Element(TM) Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... RXi Pharmaceuticals Corporation (NASDAQ: ... developing and commercializing innovative therapies addressing major unmet ... has been granted a patent by the United ... delivery system for delivering its "original" RNAi compounds ... treatment of diseases with an inflammatory component. Potential ...
(Date:9/17/2014)... Beckman Coulter , a global leader in ... its agreement with Personify for an additional ... will continue to streamline the Beckman Coulter talent acquisition ... time-to-fill, time-to-source and a deep reduction to cost-per-hire. , ... based on the success of our partnership over the ...
(Date:9/17/2014)... 2014 First antibacterial ... a truly novel class of anti-infective in ... a biopharmaceutical company developing a truly novel ... has secured £4.0m ($6.4m) to advance the ... a range of Gram-positive infections including  Clostridium ...
(Date:9/17/2014)... 2014 The Pistoia Alliance, a ... the barriers to innovation in life sciences R&D ... Carmen Nitsche as Executive Director Business Development North ... global reach. , Carmen joins the Pistoia Alliance ... Development. At Accelrys, she managed various life sciences ...
Breaking Biology Technology:RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 2RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 4Beckman Coulter Signs 3-year RPO Contract with Personify 2Beckman Coulter Signs 3-year RPO Contract with Personify 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7Pistoia Alliance Expands Business Development with Appointment of Carmen Nitsche 2
... TSX symbol: SBS, CALGARY, Oct. 17 /PRNewswire-FirstCall/ ... (TSX:SBS), today announced that it has reached an,agreement ... funding for the,development of Botaneco as an independent ... a 27-month period, beginning in the fourth,quarter of ...
... KYPH ) announced today that its stockholders approved ... MDT ) at a special,meeting of stockholders held ... Kyphon entered into a,definitive merger agreement with Medtronic, pursuant ... shares of Kyphon common stock for,$71.00 per share in ...
... employed for a variety of uses including composite materials, ... proven useful for these purposes, no one really knows ... For example, how do nanotubes and chemical functional groups ... this question could lead to improvements in future nano ...
Cached Biology Technology:Botaneco obtains $2.4 million in funding from AVAC 2Botaneco obtains $2.4 million in funding from AVAC 3Kyphon Stockholders Approve Merger with Medtronic 2Researchers measure carbon nanotube interaction 2
(Date:9/17/2014)... complex social behavior by studying nonhuman mammals and primates, ... With their unusually large brains relative to their body ... social environment---not merely in a large population of cooperating ... dynamic setting of alliances and competitors. The same is ... and social carnivores, like hyenas and lions. , A ...
(Date:9/16/2014)... NEW YORK (17 September, 2014)More than $100 trillion ... megatons of annual carbon dioxide (CO2)a 40 percent ... by 2050 if the world expands public transportation, ... new report released by the University of California, ... Policy (ITDP). , Further, an estimated 1.4 ...
(Date:9/16/2014)... -- Each tree species has its own bacterial identity. ... colleagues from other institutions who studied the genetic fingerprints ... a Panamanian island. , "This study demonstrates for the ... and with different ecological strategies possess very different microbial ... Kembel, a former postdoctoral researcher in the UO,s Institute ...
Breaking Biology News(10 mins):Being social: Learning from the behavior of birds 2Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 2Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 3Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 4Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 5Microbiome research shows each tree species has a unique bacterial identity 2
... MADISON, WI, OCTOBER 12, 2009 Areas of ... and recreational (not grazing) purposes, i.e. "urban grasslands" are ... are over 150,000 km2of urban grasslands in the U.S. ... about nutrient runoff to streams, lakes, and estuaries and ...
... by a research group at the Sahlgrenska Academy at the ... of glandular cancer usually in the head and neck and ... to quicker and better diagnosis and more effective treatment. ... Proceedings of the National Academy of Sciences (PNAS). ...
... graphene more useful in electronics applications, Kansas State University ... graphene. Vikas Berry is a K-State assistant professor ... material only a single atom thick and discovered just ... thus controlling its electronics properties -- Berry and Kabeer ...
Cached Biology News:Nitrogen mysteries in urban grasslands 2Nitrogen mysteries in urban grasslands 3New cancer gene discovered 224-carat gold 'snowflakes' improve graphene's electrical properties 2
...
...
...
... Weight DNA Markers are suitable for sizing linear ... low-percentage agarose gels. The 13 bands consist of ... digests of Lambda DNA (cIind1ts857 Sam7). Ethidium bromide ... asterisk (8271 bp 8612 bp 12220 bp and ...
Biology Products: